We recently published a list of 13 Most Profitable Growth Stocks to Buy Now. In this article, we are going to take a look at ...

The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.

Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Pfizer’s acquisition of Seagen in December 2023 added antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — to its cancer portfolio. Adcetris sales of $218 million ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

including Darzalex ® and Tivdak ® an ADC marketed for the treatment of cervical cancer. Dr. Lisby holds a Doctor of Medical Science (D.MSc.) and M.D. from the University of Copenhagen. Robin Carr Ph.D ...